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Simian virus 40 (SV40) is associated with some systemic non-Hodgkin’s lymphomas (NHL) among HIV-positive patients, based on
assays for viral DNA sequences. To investigate the possible production of the viral transforming protein, we examined age-matched case–
control specimens from patients with HIV/AIDS for the expression of SV40 large tumor antigen (T-ag). Masked specimens initially
examined by polymerase chain reaction (PCR) for polyomavirus and herpesvirus DNA sequences were assessed for the expression of SV40
T-ag and phenotypic lymphocyte markers by immunohistochemistry (IHC). Fifty-five systemic NHL and 25 nonmalignant lymphoid and
malignant nonlymphoid tissue control cases from two HIV community programs in Texas and New Jersey were scored for IHC positivity
without knowledge of the PCR results. IHC showed expression of SV40 T-ag among B-cell lymphomas, whereas none of the control tissue
samples were positive for T-ag (12/55, 22% vs. 0/25, 0%; P = 0.01). SV40 T-ag expression was detected only in B-cell lymphoma specimens
that contained SV40 DNA sequences. Not all lymphoma cells in a positive specimen stained for T-ag, and the reaction was lower intensity
than observed in SV40 hamster tumors. SV40 T-ag was demonstrated in both primary and recurrent tumors from one patient. A germinal
center B-cell-like (GCB) profile was more frequently expressed by SV40-positive tumors than in Epstein–Barr virus (EBV)-related
lymphomas (10/12, 83% vs. 6/13, 46%; P = 0.05), whereas a non-GCB phenotype was more frequent in EBV-positive than in SV40-positive
lymphomas (7/13, 54% vs. 2/12, 17%; P = 0.05). This study shows that SV40 gene expression occurs in a fraction of cells in some B-cell
lymphomas among patients with HIV/AIDS.
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Immunosuppression related with progression of HIV infec-
tion substantially increases the risk of some neoplasias,
including non-Hodgkin’s lymphoma (NHL) (Butel, 2000;
Centers for Disease Control and Prevention, 1992; Engels
and Goedert, 2005; Fisher and Fisher, 2004; International
Agency for Research on Cancer, 1996; Mueller, 1999).
NHL is a common malignancy in HIV-infected patients and
can be divided into systemic and primary central nervous
system lymphomas (Fisher and Fisher, 2004; Mueller,
1999). Some NHL in HIV-infected patients have been005) 38 – 46
Table 1
Morphology and viral DNA sequences among AIDS-related systemic non-
Hodgkin’s lymphoma and control tissues from HIV-positive patientsa
Type of sample No. of
samples
EBV DNA
positive, n (%)
SV40 DNA
positive, n (%)
Lymphomas
Diffuse large B-cell 43 13 (31) 12 (28)
Burkitt 5 3 (60) 0 (0)
Malignant lymphoma 3 0 (0) 0 (0)
Follicular 1 0 (0) 0 (0)
T-cell 3 0 (0) 0 (0)
Total lymphomas 55b 16 (29) 12 (22)c
Control tissues
Kaposi sarcoma 5 0 0 (0)
Lymph nodes 10 6 0 (0)
Lung 3 0 0 (0)
Spleen 4 2 0 (0)
Liver 3 0 0 (0)
Total control tissues 25 8 0 (0)
a Assayed for viral DNA by PCR using primers directed against EBV
LMP2a and a conserved region of polyomavirus large T-ag. SV40-specific
products were identified by sequence analysis.
b Viral DNA results from 26 of the samples were included in earlier
reports (Vilchez et al., 2002b, 2002c).
c The 12 SV40 DNA-positive lymphomas were found to express SV40 T-
antigen (this report).
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such as Epstein–Barr virus (EBV) and human herpesvirus 8
(HHV8), or perhaps to chronic antigenic stimulation and
defective immune regulation (Butel, 2000; Centers for
Disease Control and Prevention, 1992; International Agency
for Research on Cancer, 1996; Mueller, 1999). In addition,
different studies have demonstrated that SV40 large tumor
antigen (T-ag) DNA sequences are significantly associated
with NHL (with positivity rates ranging from 11% to 43%)
in both HIV-infected and HIV-uninfected patients (David et
al., 2001; Martini et al., 1998; Nakatsuka et al., 2003; Rizzo
et al., 1999; Shivapurkar et al., 2002, 2004; Vilchez et al.,
2002b, 2002c).
The discovery of polyomavirus SV40 and its introduc-
tion into the human population is related, at least in part, to
the development and worldwide dissemination of early
forms of the poliovirus vaccine (Butel and Lednicky, 1999;
Rollison and Shah, 2001; Stratton et al., 2003; Vilchez et al.,
2003b; Vilchez and Butel, 2004). These early poliovirus
vaccines were prepared using primary cell cultures derived
from rhesus monkeys, which are naturally infected with
SV40. Live SV40 survived the inactivation treatments used
to prepare the inactivated vaccines; SV40 was also present
in live, attenuated poliovirus vaccines (Proceedings of the
Second International Conference on Live Poliovirus Vac-
cines, 1960). These data led the Institute of Medicine of the
National Academies to conclude that the biological evidence
was of moderate strength that some SV40 infections in the
human population today are related to exposure from early
forms of the poliovirus vaccine and that SV40 exposure
could lead to cancer in humans under natural conditions
(Stratton et al., 2003).
The majority of studies of SV40 in lymphomas among
HIV-infected patients have measured viral DNA sequences
(David et al., 2001; Martini et al., 1998; Nakatsuka et al.,
2003; Rizzo et al., 1999; Shivapurkar et al., 2002; Vilchez et
al., 2002b, 2002c), but the presence of SV40 T-ag DNA
does not necessarily indicate synthesis of the viral trans-
forming protein. As virus-caused tumors are predicted to
exhibit the production of a viral transforming protein in at
least some cells (Butel, 2000), this marker was sought
in AIDS-related cancers. A study from Italy reported
the detection of SV40 T-ag staining in 17% of SV40
DNA-positive lymphomas from HIV-infected and -unin-
fected patients (Martini et al., 1998). In contrast, a study of
lymphoma specimens from France and Canada reported
negative results for T-ag staining, although there was no
analysis for SV40 DNA (Brousset et al., 2004). The small
number of T-ag-positive specimens on the one hand and the
lack of testing for viral DNA sequences on the other made it
difficult from those studies to evaluate the pattern of
expression of SV40 T-ag. It is recognized that the NHL
category includes several subgroups of lymphomas based on
gene expression profiles (Rosenwald et al., 2002) and
lymphocyte marker protein expression (Hans et al., 2004).
No information is available about the phenotypes of SV40-positive NHL. We report here, in an age-matched, masked,
case–control study of systemic NHL from patients with
HIV/AIDS, an examination of SV40 DNA-positive and
-negative lymphomas to determine the expression of SV40
T-ag and the phenotypic lymphocyte markers of those
opportunistic malignancies.Results
Polymerase chain reaction and DNA sequence analysis of
AIDS-related NHL and control samples
Polymerase chain reaction (PCR) analysis using primers
directed against the N-terminus of polyomavirus T-ags
(PYVfor/PYVrev) was carried out as described in Materials
and methods. SV40 T-ag DNA sequences were identified in
12 (22%) of the 55 NHL cases (Table 1). Sequence analysis
of amplified products obtained from lymphoma samples
using universal polyomavirus large T-ag primers revealed
the DNA sequences to be identical to that of the SV40 T-ag
gene. The NHL-associated sequences were proven to be
from SV40 rather than from JC or BK viruses by nucleotide
polymorphisms and the diagnostic absence of a 9 base pair
insert in this region of the large T-ag gene amplicon (Fig. 1).
All the control specimens (normal lymph node, lung, spleen,
and liver and Kaposi sarcomas) were negative for SV40
DNA (Table 1). SV40 sequences were detected significantly
more often in lymphomas than in tissue control cases (12/
55, 22% vs. 0/25, 0%; P = 0.01). Herpesviruses EBV and
HHV8 DNA sequences were detected in 16 (29%) and 0
Fig. 1. Alignment of DNA sequences from the N-terminus of the polyomavirus T-ag genes. A dot indicates identity with the nucleotide in the line above it.
Sequences of PCR products from AIDS-related systemic NHL specimens were identical to that of SV40; the T-ag sequence from one NHL is shown as an
example. The positions of the PYVfor and PYVrev primers are indicated by bolded letters. The sequence of the PYVrev primer is as shown (BKV-Dunlop nt
4388–4411, JCV-MAD-1 nt 4251–4274, SV40-776 nt 4402–4425), whereas the sequence of the PYVfor primer is complementary to that shown (BKV-
Dunlop nt 4569–4547, JCV-MAD-1 nt 4429–4407, SV40-776 nt 4552–4574).
Table 2
Frequency of SV40 T-antigen-positive cells by IHC in AIDS-related non-
Hodgkin’s lymphomas
No. of tumors
(n = 12)
% T-antigen-positive cellsa
Range (%) Results from individual
tumors (% positive cells)
1 <25 20
4 25–50 28, 29, 33, 37
7 50–75 52, 58, 60, 61, 66, 67, 70
0 >75 0
a Two investigators evaluated coded slides independently at 40
magnification, counting approximately 300 cells per slide. A third
investigator averaged the results and then unmasked the coded samples.
Negative controls were all negative. Results tabulated above are for
specimens that gave positive reactions with PAb101.
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analyses on 26 of these NHL specimens were reported
earlier (Vilchez et al., 2002b, 2002c).
Expression of SV40 T-ag in AIDS-related NHL
Immunohistochemistry (IHC) assays for SV40 T-ag were
carried out on both NHL and control tissues identified
in Table 1. Two different monoclonal antibodies were
employed, one directed against an epitope on the N-terminus
of T-ag (PAb416) and one against a C-terminal epitope
(PAb101). Positivity of staining was evaluated without
knowledge of the PCR and DNA sequencing results. Twelve
samples expressed detectable T-ag protein. After decoding
the samples and correlating the DNA and IHC results,
expression of SV40 T-ag was detected only in B-cell
lymphomas containing SV40 DNA sequences and in none
of the lymphomas and control tissues negative for viral DNA
sequences from HIV-infected patients (12/12, 100% vs. 0/68,
0%; P = 0.001). The probability that the same 12 tumors out
of 55 tested would be positive by two independent methods
(SV40 DNA amplification, SV40 T-ag expression) due to
chance is 2.279  1012. SV40 T-ag was detected only in
diffuse large B-cell lymphomas (12/43, 28%). However,
detectable expression of the viral oncoprotein varied from
tumor to tumor. The frequency of cells expressing detectable
T-ag in the positive lymphomas was quantified by inde-
pendent evaluation of coded slides (Table 2). The percentage
of T-ag-positive cells in individual tumors ranged from 20%
to 70%, with about half of the lymphomas containing over
50% positive cells. T-ag was present in the nuclei of
malignant cells of SV40 DNA-positive lymphomas and not
in reactive lymphocytes (Fig. 2). When expression of SV40
T-ag from AIDS-related NHL was compared to SV40-
induced malignancies in hamsters, lymphomas from HIV-
infected patients had a relatively lower proportion of
malignant cells expressing the viral oncoprotein and with a
relatively lower intensity of reaction (Table 2, Fig. 2).Antibody PAb101 generally gave stronger reactions than
PAb416. Whereas PAb101 reacted with 12 SV40 DNA-
positive samples, PAb416 gave detectable staining on only 5
of those samples.
Continued T-ag expression in recurrent tumors
Three specimens collected at different times from a
patient with an SV40-positive NHL showed consistent
expression of the viral protein (Fig. 3). The primary tumor
expressed T-ag, as did relapse specimens at 32 and 36
months after the original diagnosis. Positive staining
reactions with both PAb101 and PAb416 are shown.
Immunophenotyping of AIDS-related NHL
Morphologic analysis indicated that the majority of
lymphomas in patients with HIV/AIDS were diffuse large
B-cell (Table 1). Recent gene expression profiling of this
type of lymphoma among HIV-negative patients showed
that this single diagnostic category included more than
one molecularly distinct disease (Hans et al., 2004;
Fig. 3. Expression of SV40 T-ag in recurrent tumors from an HIV-positive
patient. (A) Original biopsy of an SV40 DNA-positive AIDS-related NHL
from a 46-year-old HIV-infected patient stained with PAb101. (B) Relapse
tumor specimen obtained 32 months after the original biopsy, stained with
PAb101. (C and D) Relapse tumor specimen obtained 32 months after
original biopsy, stained with PAb416. (E) An SV40 DNA-negative
lymphoma from another patient, stained with PAb416. No T-ag was
detected. (F) Relapse tumor specimen from patient shown in panel A,
obtained 36 months after original biopsy, stained with PAb416. Arrows
point to representative SV40 T-ag-positive cells. Original magnification for
panels A, B, C, and F, 40. Panels D and E, 100.
Fig. 2. SV40 T-ag expression in AIDS-related non-Hodgkin’s lymphoma.
(A) SV40-induced hamster tumor stained with PAb101 as a positive
control. (B) Expression of CD20 (indicative of B-cells) by lymphoma cells.
(C and D) Expression of nuclear SV40 T-ag in malignant B-cells in an
SV40 DNA-positive tumor from a 42-year-old HIV-infected patient, stained
with PAb101. (E) Expression of SV40 T-ag in an SV40 DNA-positive
tumor from a 29-year-old HIV-infected patient, stained with PAb416. (F)
An SV40 DNA-negative diffuse large B-cell lymphoma from a 36-year-old
HIV-infected patient reacted with PAb101; no T-ag was detected. (G)
Control reaction on an SV40 DNA-negative reactive lymph node specimen
from an HIV-infected subject; cells did not react with PAb101. Arrows
point to representative SV40 T-ag-positive cells. A lower proportion of
lymphoma cells expressed nuclear SV40 T-ag and the reaction was less
intense, as compared to the hamster tumor. Original magnification for all
panels (except panel D), 40. Panel D, 100.
Table 3
Phenotypic features of diffuse large B-cell lymphoma in HIV-positive
individuals
Virus DNA
by PCR
No. of samples
tested
B-cell markers by IHCa
CD10,
n (%)
bcl-6,
n (%)
MUM1,
n (%)
EBV 13 6 (46) 0 (0) 13 (100)
SV40 12 10 (83) 3 (25) 6 (50)
No virus 18 18 (100) 3 (17) 10 (56)
Total 43 34 (79) 6 (14) 29 (67)
a Germinal center B-cell-like: CD10 positive; CD10 and bcl-6 positive; or
CD10 negative, bcl-6 positive, and MUM1 negative. Non-germinal center
B-cell-like: CD10 and bcl-6 negative; or CD10 negative, bcl-6 positive, and
MUM1 positive.
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consists of at least three distinct gene expression sub-
groups, known as germinal center B-cell-like (GCB),
activated B-cell-like (ABC), and type 3. This last group
(type 3) was recognized to be a heterogeneous cluster that
behaved in a manner similar to the ABC group. Thus, we
examined B-cell markers by IHC to determine the subgroup
(GCB-like and non-GCB-like) of NHL associated with
DNA viruses (EBV or SV40) in HIV-positive individuals
(Table 3). Of 43 diffuse large B-cell lymphomas, 34 (79%)
were considered GCB-like and 9 (21%) were classified
as non-GCB-like. A GCB profile was more frequently
expressed in SV40-positive tumors than in EBV-related
lymphomas (10/12, 83% vs. 6/13, 46%; P = 0.05). In
contrast, a non-GCB phenotype was more frequent in EBV-positive than in SV40-positive lymphomas (7/13, 54% vs.
2/12, 17%; P = 0.05).
Clinical and laboratory correlations
Clinical data on the 12 patients found to have SV40-
positive lymphomas are reported in Table 4. SV40-positive
patients were from both the Texas and New Jersey hospitals.
Nine of the patients (75%) were minorities, perhaps
reflecting the increasing numbers of minorities in the AIDS
epidemic and/or the fact the specimens for this study were
obtained from community hospitals serving large minority
populations. Four of the patients (33%) were female. The
median CD4+ T-cell count of patients with SV40-positive
NHL was 58 (range 2–466). It is notable that four patients
Table 4
Characteristics of HIV-1 infected patients with SV40-positive systemic non-
Hodgkin’s lymphoma
Casea Year of birth Gender Race/ethnicity Nadir CD4+
T-cell count
1 1946 Mb African-American 130
2 1947 M African-American 130
3 1955 M African-American 65
4 1957 M Hispanic 52
5 1957 F African-American 2
6 1958 M Caucasian 11
7 1959 M Hispanic 126
8 1962 F Caucasian 2
9 1965 F African-American 20
10 1966 M Hispanic 25
11 1967 M Hispanic 193
12 1970 F Caucasian 466
a Nine of the patients were on anti-retroviral therapy (patients 3, 4, and 9
were not).
b M = male; F = female.
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born after 1963, recognized as free from the use of SV40-
contaminated vaccines in the United States (Stratton et al.,
2003; Vilchez et al., 2003b).Discussion
This study showed that SV40 T-ag protein was expressed
in B-cell lymphomas from HIV-infected patients that
contained SV40 T-ag DNA sequences and in none of the
lymphoma and control samples that were negative for viral
DNA sequences. The patterns of reactivity support the
specificity of the T-ag reactions. Two monoclonal antibodies
directed toward different T-ag epitopes gave positive
staining on SV40 DNA-positive NHL. One antibody was
more reactive than the other, possibly due to differing
effects of tissue fixation on the T-ag epitopes. The negative
results obtained with coded control specimens that were
handled in parallel were evidence that the positive reactions
were not due to spurious staining. SV40 DNA-negative
NHL, masked as to viral PCR results and processed at the
same time, did not stain, arguing against the antigen
retrieval procedure exposing an unknown lymphoma-
specific nonviral antigen that could react with the anti-
bodies. Further, the detection of T-ag in multiple specimens
tested under code from an individual who underwent relapse
provides further indications of the reliability of the assay.
There was a notable difference in the intensity of T-ag
staining between SV40 DNA-positive human NHL and
SV40-induced hamster tumors. Not only was the intensity
weaker in the NHL, a lower percentage of cells stained in
the human tumors (20% to 70% vs. 90% in the hamster
tumors). This observation suggests that the NHL cells
contain lower steady-state levels of T-ag, perhaps reflecting
reduced stability of T-ag or increased degradation rates, due
to unknown reasons. It would be informative to identify T-ag/cellular protein complexes in lymphoma cells, but such
studies could not be performed on the paraffin-embedded,
fixed tissue available. It is possible also that the tissue
fixation procedures used in different clinical laboratories
were more damaging to T-ag in the lymphoma cells than
was the method used to fix the hamster tumors, resulting in
weaker staining in NHL. We do not know if cells in an
SV40 DNA-positive lymphoma that appeared negative for
staining expressed low amounts of T-ag undetectable by
IHC. Alternatively, it may be that the T-ag-negative cells
had lost the viral genome because tumor progression and
accumulation of mutations in the cell had inactivated
cellular growth control checkpoints and made functional
T-ag dispensable. To address these questions, quantitative
assays and sensitive in situ hybridization approaches will
need to be applied to determine the viral load in SV40-
positive NHL and the number of malignant cells that contain
viral DNA. Such assays could not be carried out here
because the limited amounts of tissue available from biopsy
specimens had been exhausted.
In the collection of lymphomas from HIV-positive
patients examined in the present study, 22% were found to
be SV40 DNA positive (28% of diffuse large B-cell
lymphomas were SV40 positive). The frequency of SV40
positivity reported for lymphomas among HIV-uninfected
patients (or those of unknown HIV status) has varied from
less than 20% of tumors tested (David et al., 2001; Martini
et al., 1998; Nakatsuka et al., 2003; Rizzo et al., 1999) to
greater frequencies, reaching over 40% of specimens
positive (Shivapurkar et al., 2002, 2004; Vilchez et al.,
2002c; F. Samaniego, S. Wang, D. Young, and S. Wang,
unpublished). Studies from Southern Spain and Scotland
failed to detect evidence of SV40 infections in HIV-negative
patients with lymphoma (Capello et al., 2003; De Sanjose et
al., 2003; MacKenzie et al., 2003). These differences in
results may reflect varying prevalence of SV40 infections in
different geographic regions, technical issues related to
sample processing, characteristics of the specific patient
populations that were the sources of specimens, or the
inclusion of many T-cell neoplasias or EBV-positive
lymphomas (SV40 is seldom found in the latter types of
cancers). Finally, the presence of unknown cofactors that
synergize with SV40 may be necessary for SV40-positive
tumors to develop.
The present analysis found that 33% of SV40-positive
NHL cases occurred among individuals born after the period
of use of SV40-contaminated vaccines in the United States.
This observation is in agreement with studies of other
human malignancies which found that SV40 was associated
with some cancer cases in children and young adult patients
not exposed to contaminated poliovirus vaccines, suggest-
ing that SV40 is causing infections in humans today
(Bergsagel et al., 1992; Lednicky et al., 1995, 1997; Malkin
et al., 2001; Vilchez et al., 2002c; A. Meneses, D. Lopez-
Terrada, J.S. Butel and R.A. Vilchez, unpublished).
Although it appears that patients with iatrogenic and/or
R.A. Vilchez et al. / Virology 342 (2005) 38–46 43acquired immunosuppression are a population at risk for
SV40-related disease (David et al., 2001; Li et al., 2002;
Martini et al., 1998; Milstone et al., 2004; Rizzo et al., 1999;
Shivapurkar et al., 2002; Vilchez et al., 2002b, 2002c), the
natural history and dynamics of SV40 infections in this
growing patient population are not clear. Alterations in
cellular immunity in patients with HIV/AIDS may allow
conditions favorable for SV40 replication and pathogenesis
in humans.
There was a recent report describing plasmid contami-
nation of human specimens in the laboratory (Lo´pez-Rı´os et
al., 2004). The authors suggested that plasmid contamina-
tion could be the source of some SV40 sequences detected
in human material. Rigorous precautions taken in our
laboratory to guard against contamination are described in
Materials and methods. It should be noted that plasmid
contamination during sample processing, if it were to occur,
would also affect control tissues and would not result in
viral protein expression detectable by IHC in paraffin-
embedded tissues.
An association of SV40 with diffuse large B-cell
lymphomas with a GCB profile was shown here, although
only small numbers of specimens were examined. GC B-
cells are poised for apoptosis unless they are rescued by
positive stimuli (Janeway et al., 2001) and inhibition of
apoptosis is a feature of tumorigenesis by certain oncogenic
viruses, including SV40 (Cole and Tevethia, 2002; Cuconati
and White, 2002; Hatzivassiliou and Mosialos, 2002;
Jackson and Storey, 2000; Portis et al., 2001; Thomson,
2001; Tsai et al., 2000). Promoter hypermethylation of
tumor suppressor genes is a recognized mechanism of gene
silencing in some human malignancies (Esteller, 2002). A
relationship between SV40 and hypermethylation of the
RASSF1A gene has been observed in malignant mesothe-
liomas (Toyooka et al., 2001) and during transformation of
mesothelial cells in vitro (Toyooka et al., 2002). Death-
associated protein kinase (DAPK) plays a role in apoptosis
pathways in B-lymphocytes (Ng, 2002; Reddy et al., 2003)
and hypermethylation of the DAPK gene occurred more
frequently in SV40-positive than in SV40-negative NHL
(Shivapurkar et al., 2004). SV40 reportedly immortalized
human primary B-lymphocytes (Kanki, 1994) and SV40-
positive human lymphoblastoid B-cell lines were more
tumorigenic in SCID mice than were SV40-negative B-cell
lines (Dolcetti et al., 2003). Taken together, these data
suggest that SV40 has the ability to infect and alter human
B-cells. This present study does not reveal the molecular
mechanism of any potential SV40 involvement in lympho-
magenesis. However, the continued expression of T-ag by
recurrent tumors in a patient with relapse (Fig. 3) suggests
that T-ag may have provided some advantage for the
survival of those tumor cells. Future studies are needed to
address the functional effects of T-ag expression on the
properties of human lymphocytes and lymphoma cells.
In conclusion, expression of SV40 T-ag in a fraction of
lymphoma cells suggests that SV40-encoded functions maybe active in some B-cell lymphomas among HIV-infected
patients. IHC can provide information on the expression of
viral genes, but it should be considered only one of multiple
approaches for the detection of SV40 markers in human
malignancies (Rollison and Shah, 2001). The usefulness of
this technique as a primary detection tool for SV40 is
limited by the deleterious effects tissue fixation methods
may have on T-ag, the relatively low intensity of positive
staining, and the unknown prevalence of SV40 infections in
different geographic areas. As therapies improve the
survival of HIV-positive patients, the risk of developing
systemic NHL may increase. Studies using sensitive,
molecular techniques are needed to define the prevalence,
dynamics, and consequences of SV40 infections in this
population.Materials and methods
Patients and NHL samples
Forty-five of the study cases of systemic NHL were
identified from a prospective registry of AIDS-related
lymphomas at the Baylor Center for AIDS Research of
HIV-positive adult patients attending the Harris County
Hospital District (HCHD) and the Veterans Affairs Medical
Center (VAMC), Houston, TX. Briefly, the database contains
the date of diagnosis of HIV infection, patient demographics,
date of diagnosis of the malignancy, anatomic location of the
tumor, histologic type, clinical staging at the time of
diagnosis, chemotherapy, and outcome of treatment. Other
information recorded in the database includes the CD4+ T-
cell count, HIV RNAviral load in blood, and history of anti-
retroviral therapy (Vilchez et al., 2001, 2002a, 2002b,
2003a). In addition, 10 systemic NHL cases were identified
and provided from the HIV/AIDS program at Raritan Bay
Medical Center, Perth Amboy, NJ. Control specimens
included malignant (Kaposi sarcoma; n = 5) and non-
malignant lymphoid (reactive lymph nodes; n = 10) and
nonlymphoid tissue (lung, spleen, liver; n = 10) from age-
matched HIV-positive patients from the same institutions.
Institutional Review Board approval was obtained from each
institution. The demographic characteristics of the two
groups were comparable with respect to age, gender, and
mean CD4 cell counts. HIV-positive patients with systemic
NHL and control HIV-positive subjects had mean ages in
years of 39 T 7 (range 21–57) and 39 T 7 (range 28–58) (P =
1.0), male/female ratios of 40/15 and 18/7 (P = 0.9), and
mean CD4 cell counts of 126 T 139 (range 2–667) and 165 T
185 (range 2–901) (P = 0.2), respectively.
Extraction of DNA, PCR, and DNA sequence analysis from
NHL and control samples
DNAs from NHL biopsies and control samples were
extracted and analyzed by PCR and DNA sequence analysis
R.A. Vilchez et al. / Virology 342 (2005) 38–4644as previously described (Lednicky et al., 1998; Vilchez et
al., 2002b, 2002c). All sample processing was performed in
a laminar flow hood within a BL3 facility free from viruses
and plasmids. The set-up of all PCR assays was performed
in the ‘‘PCR Clean Rooms’’ core facility of the Department
of Molecular Virology and Microbiology at Baylor College
of Medicine to avoid contamination of reaction mixtures. As
a further precaution, positive displacement pipetters and
barrier tip pipettes were used. Because degradation of
nucleic acids and proteins is a common problem with
formalin-fixed, paraffin-embedded tissue specimens, only
those samples from which cellular h-globin gene sequences
were amplified successfully were deemed suitable for
analysis of viral DNA sequences (Srinivasan et al., 2002).
Oligonucleotide primers and conditions used for PCR
amplification (45 cycles) of herpesviruses EBV and HHV8
and of polyomavirus SV40 have been described previously
(Bergsagel et al., 1992; Vilchez et al., 2002b, 2002c).
Primers PYVfor/PYVrev, directed at a conserved sequence
in the amino (N)-terminus of the large T-ag gene of the three
polyomaviruses (JC, BK, and SV40) able to infect humans,
were used for viral analysis of lymphoma and control
samples and the identities of SV40 PCR products were
determined by sequence analysis (Lednicky et al., 1998;
Vilchez et al., 2002b, 2002c). The results of assays for EBV,
HHV8, and SV40 DNA sequences in 26 of the AIDS-
related systemic NHL cases from the HCHD and VAMC,
Houston, TX, were included in earlier reports (Vilchez et al.,
2002b, 2002c).
Immunohistochemical analysis
Paraffin sections of 5 Am of lymphomas and control
specimens were stained with hematoxylin and eosin and
were carefully reviewed histologically by three pathologists
for morphologic features (C.J.F, J.R.M., and D.L.T.).
Lymphomas were categorized according to the World
Health Organization Classification for Neoplastic Diseases
of the Lymphoid Tissues (Jaffe et al., 2001). The antigen
retrieval procedure consisted of steaming slides in citrate
buffer (0.01 M, pH 6.0) or Tris–HCl buffer (0.1 M, pH 9.0)
for 20 min. All slides were immersed in 3% H2O2 for 10
min to block the endogenous peroxidase. Primary mouse
monoclonal antibodies and the dilutions used for the
identification of the lymphomas were CD3 (1:40; Lab
Vision Corp., Fremont, CA), CD15 (1:50; BD Biosciences,
San Jose, CA), CD20 (1:1000), CD30 (1:200), CD45
(1:500), CD246 (1:50), and bcl-2 (1:30) (DakoCytomation,
Carpenteria, CA). The described antibodies were detected
using the EnVision + Labeled Polymer Kit (DakoCytoma-
tion) following the manufacturer’s instructions. Sections
were washed three times with Tris-buffered saline (TBS),
followed by application of the liquid Diaminobenzidine
(DAB) Substrate Pack according to the manufacturer’s
(DakoCytomation) instructions. Sections were counter-
stained with Mayer’s modified hematoxylin. For detectionof SV40 T-ag, deparaffinized sections were rehydrated and
rinsed using TBS (Signet Laboratories, Inc., Dedham, MA)
three times. Sections were then incubated at 4 -C overnight
with mouse monoclonal antibodies against the N-terminus
(PAb416, Oncogene Research Products, San Diego, CA)
(epitope between residues 82 and 130) and C-terminus
(PAb101, Santa Cruz Biotechnology Inc., Santa Cruz, CA)
(epitope between residues 512 and 708) of SV40 T-ag. Each
monoclonal antibody was titered to determine the optimal
dilution to use to avoid nonspecific reactivity on normal
cells and to retain reactivity against SV40 T-ag in SV40-
infected cells. Both PAb416 and PAb101 were used at a
dilution of 1:100. After rinsing, sections were incubated
with a mouse probe-polymer reagent (Biocare Medical,
Walnut Creek, CA) for 20 min for detection and visualized
with DAB, as above. Tissues processed for IHC were
viewed microscopically and scored for cell type, the
percentage of lymphoma cells, localization of staining,
and antibody reactivity (negative or positive). SV40-
induced malignancies in hamsters were used as positive
controls (Vilchez et al., 2004).
The phenotypic features of diffuse large B-cell lym-
phoma [germinal center (GC) B-cell-like and non-GC] were
examined according to methods described previously
(Carbone et al., 2001; Hans et al., 2004; Little et al.,
2003). Primary mouse monoclonal antibodies and dilutions
used for immunophenotyping GC and non-GC diffuse large
B-cell lymphoma were CD10 (Novacastra Laboratories,
Newcastle, UK; 1:50), bcl-6 (DakoCytomation; 1:100), and
MUM1 (DakoCytomation; 1:100). Antibodies were de-
tected as described above for lymphoma markers. As CD10
and bcl-6 are markers of germinal center B-cells, cases were
identified as GCB origin if CD10 was positive or if both
CD10 and bcl-6 were positive. If both CD10 and bcl-6 were
negative, the case was designated as non-GCB. MUM1 is
expressed in plasma cells and the later stages of B-cell
development and is recognized to be associated with the
ABC group in gene expression profiles of lymphomas in
HIV-negative patients (Hans et al., 2004). If CD10 was
negative and bcl-6 was positive, the expression of MUM1
determined the group. If MUM1 was negative, the case was
identified as GCB. If MUM1 was positive, the case was
defined as non-GCB.
Statistical analysis
Group proportions among cases and control groups were
tested with the Z test of proportions with use of the STATA
6.0 software package (College Station, TX).Acknowledgments
This study was supported in part by grant number 6147-
03 from the Leukemia and Lymphoma Society, grant
number AI36211 from the National Institute of Allergy
R.A. Vilchez et al. / Virology 342 (2005) 38–46 45and Infectious Diseases, and grant number CA104818 from
the National Cancer Institute.
We thank Claudia Kozinetz for statistical advice and the
staff members of the Pathology Departments at the Harris
County Hospital District and Veterans Affairs Medical
Center in Houston, TX, and the members of the Pathology
and Medicine Departments and Immunology Unit at Raritan
Bay Medical Center, Perth Amboy, NJ, for their assistance
in the collection of data and specimens.References
Bergsagel, D.J., Finegold, M.J., Butel, J.S., Kupsky, W.J., Garcea, R.L.,
1992. DNA sequences similar to those of simian virus 40 in
ependymomas and choroid plexus tumors of childhood. N. Engl. J.
Med. 326, 988–993.
Brousset, P., de Araujo, V., Gascoyne, R.D., 2004. Immunohistochemical
investigation of SV40 large T antigen in Hodgkin and non-Hodgkin’s
lymphoma. Int. J. Cancer 112, 533–535.
Butel, J.S., 2000. Viral carcinogenesis: revelation of molecular mechanisms
and etiology of human disease. Carcinogenesis 21, 405–426.
Butel, J.S., Lednicky, J.A., 1999. Cell and molecular biology of simian
virus 40: implications for human infections and disease. J. Natl. Cancer
Inst. 91, 119–134.
Capello, D., Rossi, D., Gaudino, G., Carbone, A., Gaidano, G., 2003.
Simian virus 40 infection in lymphoproliferative disorders. Lancet 361,
88–89.
Carbone, A., Gloghini, A., Larocca, L.M., Capello, D., Pierconti, F.,
Canzonieri, V., Tirelli, U., Dalla-Favera, R., Gaidano, G., 2001.
Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1
defines novel histogenetic subsets of human immunodeficiency virus-
related lymphomas. Blood 97, 744–751.
Centers for Disease Control and Prevention, 1992. 1993 revised classi-
fication system for HIV infection and expanded surveillance case
definition for AIDS among adolescents and adults. Morb. Mortal. Wkly.
Rep. 41, 1–19.
Cole, S.L., Tevethia, M.J., 2002. Simian virus 40 large T antigen and two
independent T-antigen segments sensitize cells to apoptosis following
genotoxic damage. J. Virol. 76, 8420–8432.
Cuconati, A., White, E., 2002. Viral homologs of BCL-2: role of apoptosis
in the regulation of virus infection. Genes Dev. 16, 2465–2478.
David, H., Mendoza, S., Konishi, T., Miller, C.W., 2001. Simian virus 40
is present in human lymphomas and normal blood. Cancer Lett. 162,
57–64.
De Sanjose, S., Shah, K.V., Domingo-Domenech, E., Engels, E.A., De
Sevilla, A.F., Alvaro, T., Garcia-Villanueva, M., Romagosa, V.,
Gonzalez-Barca, E., Viscidi, R.P., 2003. Lack of serological evidence
for an association between simian virus 40 and lymphoma. Int. J.
Cancer 104, 522–524.
Dolcetti, R., Martini, F., Quaia, M., Gloghini, A., Vignocchi, B., Cariati, R.,
Martinelli, M., Carbone, A., Boiocchi, M., Tognon, M., 2003. Simian
virus 40 sequences in human lymphoblastoid B-cell lines. J. Virol. 77,
1595–1597.
Engels, E.A., Goedert, J.J., 2005. Human immunodeficiency virus/acquired
immunodeficiency syndrome and cancer: past, present, and future.
J. Natl. Cancer Inst. 97, 407–409.
Esteller, M., 2002. CpG island hypermethylation and tumor suppressor
genes: a booming present, a brighter future. Oncogene 21, 5427–5440.
Fisher, S.G., Fisher, R.I., 2004. The epidemiology of non-Hodgkin’s
lymphoma. Oncogene 23, 6524–6534.
Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J.,
Ott, G., Mu¨ller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S.,
Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald,
A., Staudt, L.M., Connors, J.M., Armitage, J.O., Chan, W.C., 2004.Confirmation of the molecular classification of diffuse large B-cell
lymphoma by immunohistochemistry using a tissue microarray. Blood
103, 275–282.
Hatzivassiliou, E., Mosialos, G., 2002. Cellular signaling pathways engaged
by the Epstein–Barr virus transforming protein LMP1. Front. Biosci. 7,
d319–d329.
International Agency for Research on Cancer, 1996. IARC Monographs on
the Evaluation of Carcinogenic Risks to Humans, vol. 67: Human
Immunodeficiency Virus and Human T Cell Lymphotropic Viruses.
International Agency for Research on Cancer/World Health Organiza-
tion, Lyon.
Jackson, S., Storey, A., 2000. E6 proteins from diverse cutaneous HPV
types inhibit apoptosis response to UV damage. Oncogene 19,
592–598.
Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., 2001. World Health
Organization classification of tumours. Pathology and Genetics of
Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon,
France.
Janeway, C.A., Travers, P., Walport, M., Shlomchik, M., 2001. Immuno-
biology. Garland Publishing, New York.
Kanki, T., 1994. Immortalization of human primary B lymphocytes by
simian virus 40 early region DNA. Hybridoma 13, 327–330.
Lednicky, J.A., Garcea, R.L., Bergsagel, D.J., Butel, J.S., 1995. Natural
simian virus 40 strains are present in human choroid plexus and
ependymoma tumors. Virology 212, 710–717.
Lednicky, J.A., Stewart, A.R., Jenkins III, J.J., Finegold, M.J., Butel, J.S.,
1997. SV40 DNA in human osteosarcomas shows sequence variation
among T-antigen genes. Int. J. Cancer 72, 791–800.
Lednicky, J.A., Arrington, A.S., Stewart, A.R., Dai, X.M., Wong, C., Jafar,
S., Murphey-Corb, M., Butel, J.S., 1998. Natural isolates of simian
virus 40 from immunocompromised monkeys display extensive genetic
heterogeneity: new implications for polyomavirus disease. J. Virol. 72,
3980–3990.
Li, R.M., Mannon, R.B., Kleiner, D., Tsokos, M., Bynum, M., Kirk, A.D.,
Kopp, J.B., 2002. BK virus and SV40 co-infection in polyomavirus
nephropathy. Transplantation 74, 1497–1504.
Little, R.F., Pittaluga, S., Grant, N., Steinberg, S.M., Kavlick, M.F.,
Mitsuya, H., Franchini, G., Gutierrez, M., Raffeld, M., Jaffe, E.S.,
Shearer, G., Yarchoan, R., Wilson, W.H., 2003. Highly effective
treatment of acquired immunodeficiency syndrome-related lymphoma
with dose-adjusted EPOCH: impact of antiretroviral therapy suspension
and tumor biology. Blood 101, 4653–4659.
Lo´pez-Rı´os, F., Illei, P.B., Rusch, V., Ladanyi, M., 2004. Evidence against a
role for SV40 infection in human mesotheliomas and high risk of false-
positive PCR results owing to presence of SV40 sequences in common
laboratory plasmids. Lancet 364, 1157–1166.
MacKenzie, J., Wilson, K.S., Perry, J., Gallagher, A., Jarrett, R.F., 2003.
Association between simian virus 40 DNA and lymphoma in the United
Kingdom. J. Natl. Cancer Inst. 95, 1001–1003.
Malkin, D., Chilton-MacNeill, S., Meister, L.A., Sexsmith, E., Diller, L.,
Garcea, R.L., 2001. Tissue-specific expression of SV40 in tumors
associated with the Li–Fraumeni syndrome. Oncogene 20, 4441–4449.
Martini, F., Dolcetti, R., Gloghini, A., Iaccheri, L., Carbone, A., Boiocchi,
M., Tognon, M., 1998. Simian-virus-40 footprints in human lympho-
proliferative disorders of HIV and HIV+ patients. Int. J. Cancer 78,
669–674.
Milstone, A., Vilchez, R.A., Geiger, X., Fogo, A.B., Butel, J.S.,
Dummer, S., 2004. Polyomavirus simian virus 40 infection associated
with nephropathy in a lung-transplant recipient. Transplantation 77,
1019–1024.
Mueller, N., 1999. Overview of the epidemiology of malignancy in immune
deficiency. J. Acquir. Immune Defic. Syndr. 21, S5–S10.
Nakatsuka, S.-I., Liu, A., Dong, Z., Nomura, S., Takakuwa, T.,
Miyazato, H., Aozasa, K., Osaka Lymphoma Study Group, 2003.
Simian virus 40 sequences in malignant lymphomas in Japan. Cancer
Res. 63, 7606–7608.
Ng, M.H.L., 2002. Death associated protein kinase: from regulation of
R.A. Vilchez et al. / Virology 342 (2005) 38–4646apoptosis to tumor suppressive functions and B cell malignancies.
Apoptosis 7, 261–270.
Portis, T., Harding, J.C., Ratner, L., 2001. The contribution of NF-kB
activity to spontaneous proliferation and resistance to apoptosis in
human T-cell leukemia virus type 1 Tax-induced tumors. Blood 98,
1200–1208.
Proceedings of the Second International Conference on Live Poliovirus
Vaccines 1960. Papers and Discussions Held. Pan American Health
Organization, Scientific Publication No. 50. Pan American Health
Organization, Washington, DC.
Reddy, A.N., Jiang, W.W., Kim, M., Benoit, N., Taylor, R., Clinger, J.,
Sidransky, D., Califano, J.A., 2003. Death-associated protein kinase
promoter hypermethylation in normal human lymphocytes. Cancer Res.
63, 7694–7698.
Rizzo, P., Carbone, M., Fisher, S.G., Matker, C., Swinnen, L.J., Powers, A.,
Di Resta, I., Alkan, S., Pass, H.I., Fisher, R.I., 1999. Simian virus 40 is
present in most United States human mesotheliomas, but it is rarely
present in non-Hodgkin’s lymphoma. Chest 116, 470S–473S.
Rollison, D.E.M., Shah, K.V., 2001. The epidemiology of SV40
infection due to contaminated polio vaccines: relation of the virus
to human cancer. In: Khalili, K., Stoner, G.L. (Eds.), Human
Polyomaviruses: Molecular and Clinical Perspectives. Wiley-Liss
Inc., New York, pp. 561–584.
Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E.,
Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B.,
Staudt, L.M., for the Lymphoma/Leukemia Molecular Profiling
Project, 2002. The use of molecular profiling to predict survival after
chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med.
346, 1937–1947.
Shivapurkar, N., Harada, K., Reddy, J., Scheuermann, R.H., Xu, Y.,
McKenna, R.W., Milchgrub, S., Kroft, S.H., Feng, Z., Gazdar, A.F.,
2002. Presence of simian virus 40 DNA sequences in human
lymphomas. Lancet 359, 851–852.
Shivapurkar, N., Takahashi, T., Reddy, J., Zheng, Y., Stastny, V., Collins,
R., Toyooka, S., Suzuki, M., Parikh, G., Asplund, S., Kroft, S.H.,
Timmons, C., McKenna, R.W., Feng, Z., Gazdar, A.F., 2004. Presence
of simian virus 40 DNA sequences in human lymphoid and hema-
topoietic malignancies and their relationship to aberrant promoter
methylation of multiple genes. Cancer Res. 64, 3757–3760.
Srinivasan, M., Sedmak, D., Jewell, S., 2002. Effect of fixatives and tissue
processing on the content and integrity of nucleic acids. Am. J. Pathol.
161, 1961–1971.Stratton, K., Alamario, D.A., McCormick, M.C., 2003. Immunization
Safety Review: SV40 Contamination of Polio Vaccine and Cancer. The
National Academies Press, Washington, DC.
Thomson, B.J., 2001. Viruses and apoptosis. Int. J. Exp. Pathol. 82, 65–76.
Toyooka, S., Pass, H.I., Shivapurkar, N., Fukuyama, Y., Maruyama, R.,
Toyooka, K.O., Gilcrease, M., Farinas, A., Minna, J.D., Gazdar, A.F.,
2001. Aberrant methylation and simian virus 40 Tag sequences in
malignant mesothelioma. Cancer Res. 61, 5727–5730.
Toyooka, S., Carbone, M., Toyooka, K.O., Bocchetta, M., Shivapurkar, N.,
Minna, J.D., Gazdar, A.F., 2002. Progressive aberrant methylation of
the RASSF1A gene in simian virus 40 infected human mesothelial cells.
Oncogene 21, 4340–4344.
Tsai, S.C., Pasumarthi, K.B.S., Pajak, L., Franklin, M., Patton, B., Wang,
H., Henzel, W.J., Stults, J.T., Field, L.J., 2000. Simian virus 40 large T
antigen binds a novel Bcl-2 homology domain 3-containing proapop-
tosis protein in the cytoplasm. J. Biol. Chem. 275, 3239–3246.
Vilchez, R.A., Butel, J.S., 2004. Emergent human pathogen simian virus 40
and its role in cancer. Clin. Microbiol. Rev. 17, 495–508.
Vilchez, R.A., Kozinetz, C.A., Butel, J.S., 2001. The changing incidence of
four AIDS-related malignancies in a large urban center. AIDS Patient
Care STDs 15, 405–406.
Vilchez, R.A., Kozinetz, C.A., Jorgensen, J.L., Kroll, M.H., Butel, J.S.,
2002a. AIDS-related systemic non-Hodgkin’s lymphoma at a large
community program. AIDS Res. Hum. Retroviruses 18, 237–242.
Vilchez, R.A., Lednicky, J.A., Halvorson, S.J., White, Z.S., Kozinetz, C.A.,
Butel, J.S., 2002b. Detection of polyomavirus simian virus 40 tumor
antigen DNA in AIDS-related systemic non-Hodgkin lymphoma.
J. Acquir. Immune Defic. Syndr. 29, 109–116.
Vilchez, R.A., Madden, C.R., Kozinetz, C.A., Halvorson, S.J., White, Z.S.,
Jorgensen, J.L., Finch, C.J., Butel, J.S., 2002c. Association between
simian virus 40 and non-Hodgkin lymphoma. Lancet 359, 817–823.
Vilchez, R.A., Finch, C.J., Jorgensen, J.L., Butel, J.S., 2003a. The
clinical epidemiology of Hodgkin lymphoma in HIV-infected patients
in the highly active antiretroviral therapy (HAART) era. Medicine
82, 77–81.
Vilchez, R.A., Kozinetz, C.A., Butel, J.S., 2003b. Conventional epidemio-
logy and the link between SV40 and human cancers. Lancet Oncol. 4,
188–191.
Vilchez, R.A., Brayton, C.F., Wong, C., Zanwar, P., Killen, D.E.,
Jorgensen, J.L., Butel, J.S., 2004. Differential ability of two simian
virus 40 strains to induce malignancies in weanling hamsters. Virology
330, 168–177.
